Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Common Equity (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Common Equity for 4 consecutive years, with $46.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 164.24% to $46.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.6 million, a 164.24% increase, with the full-year FY2024 number at $61.0 million, up 20.64% from a year prior.
  • Common Equity was $46.6 million for Q3 2025 at Mereo BioPharma, down from $54.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $78.6 million in Q2 2024 to a low of -$72.5 million in Q3 2024.
  • A 4-year average of $43.5 million and a median of $51.0 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 232.59% in 2024, then surged 164.24% in 2025.
  • Mereo BioPharma's Common Equity stood at $51.4 million in 2022, then fell by 1.68% to $50.5 million in 2023, then grew by 20.64% to $61.0 million in 2024, then fell by 23.57% to $46.6 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Common Equity are $46.6 million (Q3 2025), $54.2 million (Q2 2025), and $60.1 million (Q1 2025).